Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607030 | 1.00 | KDM4E (0.33) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3603051 | 0.90 | KDM4E (0.39) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3596153 | 0.88 | RXRA (0.39) | KDM4EMEN1MAPTKMT2AP2RY14 | |
| SCHEMBL3596156 | 0.88 | RXRA (0.39) | KDM4EMEN1MAPTKMT2AP2RY14 | |
| SCHEMBL3606430 | 0.84 | KDM4E (0.34) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3606435 | 0.84 | KDM4E (0.34) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3601066 | 0.84 | MAPT (0.37) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3601062 | 0.84 | MAPT (0.37) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3601992 | 0.83 | HDAC1 (0.35) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3601994 | 0.83 | HDAC1 (0.35) | KDM4EMEN1MAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | XDH, URB2, ALOX12 | KDM4E 4711/4885MEN1 3894/4885MAPT 3339/4885 |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | XDH, URB2, ALOX12 | KDM4E 4711/4885MEN1 3894/4885MAPT 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.